ClinicalTrials.gg
RecruitingNCT06119243MENOKUpdated Dec 12, 2024

Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study

An observational study in Myopia, sponsored by The University of New South Wales. Recruiting at 5 sites in 2 countries. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by The University of New South Wales · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
230
Ages
4 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Planned enrollment
11th of 46
230 · median 91
Started
2023
with 30 others
Observational
48 of 342
6 open now
Primary completion
2026-06
later than 9 of 43 live
Registered
291st of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 11th largest by planned enrollment of the 46 observational ones that give a count, is one of 31 that started in 2023, is one of 48 observational ones, reaches primary completion later than 9 of the 43 other live ones, and was the 291st registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 4 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior in myopic children and its impact on myopia control efficacy. The outcomes of this study will guide clinicians on risk management and improve responses to existing treatments for progressive myopia.

03

Conditions studied

  • Myopia

Keywords

  • Myopia
  • Myopia control
  • Progressive myopia
  • Near vision behavior
  • Outdoor activity
  • Environment
  • Light exposure
04

Who can participate

Ages eligible
4 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Myopic children will be recruited from the university based myopia control clinic. Some clinical sites have collaborated with community optometry practices so support recruitment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 6 to below 14 years old
  2. Spherical equivalent myopic refractive error greater than -0.50 D
  3. Best corrected logMAR visual acuity of 0.1 or better in each eye for 6- to 14-year-old children, and 0.2 logMAR or better than in each eye for 4 and 5-year-old children (adjusted for age-related expectations)
  4. Good ocular and general health that would not preclude them from myopia control
  5. Competent enough in English to fully understand the participant information and consent form
  6. Willing to undergo treatment to slow myopia progression for one year

Exclusion criteria

Exclusion Criteria:

  1. Strabismus at distance or near, or amblyopia
  2. Systemic or ocular conditions that may affect contact lens use (e.g. severe allergy) or refractive development (e.g. ptosis)
  3. Previous history of ocular surgery, trauma or chronic ocular disease that may affect their vision
  4. Ocular or systemic medication use which may interfere or interact with myopia treatment or ocular development
  5. Child, parents or guardians not willing to comply with treatment and/or follow-up schedule and planning to migrate or move during the one-year study duration
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
230 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • DeviceVivior

    The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.

06

What researchers measure

Primary outcomes

  1. Near viewing duration

    Duration during near tasks

    Time frame: 12 months

  2. Near viewing distance

    Distance during near tasks

    Time frame: 12 months

  3. Outdoor time

    Ambient illumination to determine time spent outdoors

    Time frame: 12 months

Secondary outcomes

  1. Objective cycloplegic central refraction

    Change in objective refraction to measure myopia progression

    Time frame: 12 months

  2. Axial length

    Change in axial length to measure myopia progression

    Time frame: 12 months

  3. Subjective cycloplegic central refraction

    Change in subjective refraction to measure myopia progression

    Time frame: 12 months

07

Study locations

3 of 5 sites recruiting
  • School of Optometry, University of California, Berkeley
    Berkeley, California 94720, United States
    Active, not recruiting

    Not enrolling at this site.

  • New England College of Optometry
    Boston, Massachusetts 02115, United States
    Recruiting
    • Fuensanta Vera-Diaz, PhD · Contact
  • State University of New York (SUNY), College of Optometry
    New York City, New York 10036, United States
    Not yet recruiting
    • Xiaoying Zhu, PhD · Contact
  • School of Optometry and Vision Science, UNSW
    Sydney, New South Wales 2052, Australia
    Recruiting
  • Optometry and Vision Science, Queensland University of Technology
    Kelvin Grove, Queensland 4059, Australia
    Recruiting
    • Emily Pieterse, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2026, 39 months after the start.

Of 89 non-industry observational studies under Myopia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's planned 39 months is above that.

Counting every sponsor, half of 98 studies reached it within 24 months; a quarter within 10 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 7, 2023
StartActual
Mar 21, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06119243
Lead sponsor
The University of New South Wales
Collaborators
Queensland University of Technology, New England College of Optometry, State University of New York College of Optometry, University of California, Berkeley
Responsible party
Pauline Kang (Senior Lecturer, The University of New South Wales) — Principal investigator
First posted
Nov 7, 2023
Start date
Mar 21, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 12, 2024

Study contacts

Pauline Kang, PhD
Contact
p.kang@unsw.edu.au
612 9065 6112

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion